Side-by-side comparison of AI visibility scores, market position, and capabilities
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
Chesapeake VA value retail (NASDAQ: DLTR) at $17.6B FY2024 revenue; Family Dollar sold for $1B (2025, vs. $9.5B acquired 2015), multi-price 3.0 format ($1.25-$7) in 2,900 stores competing with Dollar General for value shoppers.
Dollar Tree, Inc. is a Chesapeake, Virginia-based discount variety retailer — publicly traded on NASDAQ (NASDAQ: DLTR) as an S&P 500 Consumer Staples component — operating as a Fortune 200 company with approximately 16,000 stores across 48 states and five Canadian provinces through over 214,000 employees, with fiscal year 2024 revenue of $17.6 billion. The company's defining strategic development of 2025 was the completion of the sale of its Family Dollar business to Brigade Capital Management and Macellum Capital Management for just over $1 billion — a $8.5 billion write-down from the original $9.5 billion Family Dollar acquisition price in 2015, marking one of the largest retail acquisition failures in recent history. The divestiture concentrates Dollar Tree on its core namesake banner, which has undergone its own transformation: the company raised prices from $1.00 to $1.25 in 2022 (the first price increase in 36 years of the $1 fixed-price promise) and has expanded approximately 2,900 stores to the multi-price "3.0" format offering products up to $7. Founded in 1986 by Macon Brock and Doug Perry in Norfolk, Virginia as a single-price point variety store, Dollar Tree grew to become the dominant US single-price-point retailer before the ill-fated Family Dollar acquisition transformed it into a dual-banner company trying to serve both the $1-focused impulse buyer and the neighborhood dollar store shopper.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.